Cargando...
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...
Guardado en:
| Publicado en: | Cancer Lett |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/ https://ncbi.nlm.nih.gov/pubmed/25458954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|